Overview

MK0859 Dose-Ranging Study (0859-003)

Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Anacetrapib